Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Inozyme Pharma (NASDAQ:INZY) and maintained a price target of $23.
November 08, 2023 | 9:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Inozyme Pharma, maintaining a price target of $23.
The reiteration of a 'Buy' rating by a Needham analyst, along with the maintenance of a $23 price target, indicates a positive outlook for Inozyme Pharma. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100